# Alex Buchan

> Alex Buchan is a venture - series unknown investor at Northstar Ventures backing Biotechnology. See 25 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Northstar Ventures](https://shizune.co/investors/profile/northstar-ventures)
- Location: Newcastle Upon Tyne, United Kingdom
- Total investments: 25
- Last investment: Aug 2026
- Lead investor: 40%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/alex-buchan/7/187/190
- X (Twitter): https://twitter.com/Alex_E_Buchan

Alex Buchan is a venture - series unknown investor at Northstar Ventures in Newcastle Upon Tyne focused on Biotechnology and Health Care. Alex leads on our life science and bio-tech investments. As an Investment Director, Alex makes and manages investments into a wide range of technology businesses and oversees our activities in the health-tech and green-tech sectors. He is an observer on the board of several companies and is a Non-Exec Director at Femeda, a company which producesmedical devices.Alex has been interested in the life-sciences industry since completing a PhD in Microbiology/ Biotechnology at the University of Kent. He went on to hold a number of senior commercial roles in biotechnology companies, including Compugen, SDI Europe and EnSys Europe. Prior to this, Alex worked as a Stockbroker in London. Alex is also responsible for Northstar's partnership with Ignite, one of Europe's leading angel-led accelerator programmes. As part of this, Alex works as a mentor and advisor to start-up companies taking part. He also sits on the Newcastle University Equity Committee, supporting with its commercialisation activities.Outside of Northstar, Alex is a Trustee for North East charity The Lit and Phil - the largest independent library outside of London.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 7 | 28% |
| Health Care | 5 | 20% |
| Medical | 2 | 8% |
| Life Science | 2 | 8% |
| Medical Device | 2 | 8% |

19 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Venture - Series Unknown | 7 | 28% |
| Seed | 6 | 24% |
| Series A | 4 | 16% |
| Pre-Seed | 1 | 4% |
| Funding Round | 1 | 4% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 11 | 44% |
| Ireland | 1 | 4% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Advanced Electric Machines | Advanced Electric Machines Ltd (AEM) was formed in November 2016 to deliver world class motor and drivetrain systems for Low Carbon Vehicles with a focus on cost effective high performance and minimal environmental impact. AEM is focused on putting Britain ahead in the global race for the development of new low carbon propulsion technologiesaiming to use a UK manufacturing base to export products all over the world. | $21.5M | Venture - Series Unknown | Aug 04, 2026 |  |
| NunaBio | NunaBio operates as a privately-owned specialist DNA development company. NunaBio engaged in CRO (Contract Research Organizations) and CDMO (Contract Development and Manufacturing Organisation) activities. | $8.8M | Venture - Series Unknown | Apr 30, 2026 |  |
| Magnitude Biosciences | Magnitude Biosciences is a biotechnology firm combine experience in ageing research, the nematode C. elegans and automation. | $946K | Seed | May 27, 2025 |  |
| Nanovery | Founded by scientists specialised in Nanotechnology, Medicinal Chemistry and Artificial Intelligence, we are on a mission to enable early detection of cancer through a rapid and affordable blood test Backed by academics at top universities, clinicians, industrial leaders, and Entrepreneur First. | $1.4M | Venture - Series Unknown | Apr 10, 2025 |  |
| Newcells Biotech | Newcells Biotech are experts in the production of induced pluripotent stem cells (iPSCs) and their differentiation into a wide range of reliable and reproducible cell and tissue types. Their focus is to provide customers engaged in drug discovery, pre-clinical development and disease mechanism investigation, with the best quality cells andservices. | $1.5M |  | Dec 05, 2024 |  |
| Amlo Biosciences | AMLo Biosciences has identified two proteins (AMBLor™) in the skin overlying the primary tumour that are lost in high-risk melanoma. | $2M | Venture - Series Unknown | Dec 03, 2024 |  |
| CellRev | high expertise in the designing and testing of self-assembling peptides providing different benefits when culturing adherent cells in vitro. |  | Seed | Sep 23, 2024 |  |
| NunaBio | NunaBio operates as a privately-owned specialist DNA development company. NunaBio engaged in CRO (Contract Research Organizations) and CDMO (Contract Development and Manufacturing Organisation) activities. | $1.1M | Seed | Sep 03, 2024 |  |
| Lightox | Lightox has developed a unique range of molecular tools for use in imaging, therapeutics and assay development. These unique probes are smaller than any other commercially available fluorescent product. They offer the option of using our technologies as freely-moving probes that readily incorporate into cells or with a range of flexible linkers togive specificity to your unique applications and research needs. | $1.9M | Venture - Series Unknown | May 03, 2024 |  |
| VRAI | First and foremost, they are a content creation company specialising in virtual reality production. They are visual storytellers embracing this new medium as a way of creating immersive, engaging content.Their pioneering methodology takes elements from our diverse background. We use techniques from narrative cinema, from visual effects, fromexhibition design, from gaming, from brand management and combine them in new exciting ways to help you tell your story. |  | Venture - Series Unknown | Apr 08, 2024 |  |

10 of 25 investments shown.

## Co-investors
- [Mercia Asset Management](https://shizune.co/investors/profile/mercia-asset-management) — VC Fund, 3 deals together
- [North East Fund](https://shizune.co/investors/profile/north-east-innovation-fund) — VC Fund, 3 deals together
- [Maven Capital Partners](https://shizune.co/investors/profile/maven-capital-partners) — VC Fund, 2 deals together
- [Mercia Asset Management](https://shizune.co/investors/profile/mercia-technologies) — VC Fund, 2 deals together
- [Mercia Ventures](https://shizune.co/investors/profile/mercia-ventures) — VC Fund, 2 deals together
- [Ascension](https://shizune.co/investors/profile/ascension-ventures-limited) — VC Fund, 1 deal together

## About Northstar Ventures

VC Fund · Newcastle Upon Tyne, United Kingdom

Northstar Ventures is a venture capital firm investing in innovative solutions to help solve the most pressing societal issues we have today.  Our ticket sizes range from £100k to £500k into early stage tech companies. We provide added value in leveraging our network of university partners, funders, non-executive directors and talent to supporteach investment. We are based in the North East of England and aim to invest in companies that bring talent, jobs and growth to the region

5 contacts available at Northstar Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Alasdair Greig | Director | https://shizune.co/investors/profile/alasdair-greig |
| Ian Richards | Director | https://shizune.co/investors/profile/ian-richards |
| Alex Buchan | Investment Director | https://shizune.co/investors/profile/dr-alex-buchan |
| Dominic Endicott | Director | https://shizune.co/investors/profile/dominic-endicott |
| Emma O’Rourke | Finance Director | https://shizune.co/investors/profile/emma-orourke |

## Similar investors

### Similar stage
- [Bossa Invest](https://shizune.co/investors/profile/bossanova-investimentos) — VC Fund
- [Almi Invest](https://shizune.co/investors/profile/almi-invest) — VC Fund
- [Korea Credit Guarantee Fund](https://shizune.co/investors/profile/korea-credit-guarantee-fund) — VC Fund

## FAQ

### What does Alex Buchan invest in?

Alex Buchan invests primarily in Biotechnology, Health Care and Medical startups, most often at Venture - Series Unknown and Seed stage. Most of the 25 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Alex Buchan last invest?

The most recent investment recorded for Alex Buchan closed in Aug 2026. Shizune tracks 25 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co